Evoke Pharma Inc
NASDAQ:EVOK

Watchlist Manager
Evoke Pharma Inc Logo
Evoke Pharma Inc
NASDAQ:EVOK
Watchlist
Price: 21.9 USD -2.23% Market Closed
Market Cap: 18.7m USD

Evoke Pharma Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Evoke Pharma Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Evoke Pharma Inc
NASDAQ:EVOK
Cash from Operating Activities
-$3.3m
CAGR 3-Years
18%
CAGR 5-Years
11%
CAGR 10-Years
11%
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$24.2B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$16.6B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
25%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$13.1B
CAGR 3-Years
-21%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$17.1B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
9%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$16.1B
CAGR 3-Years
26%
CAGR 5-Years
19%
CAGR 10-Years
17%
No Stocks Found

Evoke Pharma Inc
Glance View

Market Cap
18.7m USD
Industry
Pharmaceuticals

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

EVOK Intrinsic Value
137.22 USD
Undervaluation 84%
Intrinsic Value
Price

See Also

What is Evoke Pharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-3.3m USD

Based on the financial report for Sep 30, 2025, Evoke Pharma Inc's Cash from Operating Activities amounts to -3.3m USD.

What is Evoke Pharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
11%

Over the last year, the Cash from Operating Activities growth was 38%. The average annual Cash from Operating Activities growth rates for Evoke Pharma Inc have been 18% over the past three years , 11% over the past five years , and 11% over the past ten years .

Back to Top